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1. Introduction
Diabetes mellitus is a multi-factorial disease caused by a combination of genetic and environ‐
mental factors. Although insulin resistance and dysregulation of glucose and lipid homeostasis
are the primary hallmarks of the disease, it is now well accepted that the morbidity and
mortality associated with diabetes mostly result from micro- and macro-vascular complica‐
tions [1]. An early step in the pathogenesis of the vascular complications of diabetes is the
development of endothelial dysfunction which is characterised by a decrease in nitric oxide
(NO) bioavailability, prostacyclin production and a general reduction in the anti-thrombo‐
genic properties of vascular wall [2]. Diabetes is also characterised by an alteration of platelet
function. Indeed, platelets from patients with type 1 or type 2 diabetes are hyperreactive and
demonstrate increased adhesiveness as well as exaggerated aggregation and thrombus
formation. Several mechanisms have been reported to mediate the hyperreactivity of platelets
from diabetic patients including morphological changes such as increased mean platelet
volume and accelerated platelet turnover, biochemical changes such as increased reactive
oxygen species (ROS) production, increased synthesis of thromboxane A2 (TXA2) and
thrombin and a dysregulated Ca2+ homeostasis. Platelets from diabetic patients also demon‐
strate increased surface expression of adhesion proteins such as P-selectin and the αIIbβ3
integrin and reduced membrane fluidity. These changes characteristic of the “diabetic platelet”
have been mostly attributed to the metabolic dysregulation associated to the insulin resistance
and dyslipidemia. However, given that platelet hyperreactivity has also been found in patients
with type 1 diabetes mellitus it is suggested that hyperglycemia alone can account for at least
part of the altered platelet response in patients with diabetes mellitus. Oxidative stress which
characterizes both types of diabetes has also been shown to be an important factor mediating
the phenotypic changes of diabetic platelets. In this chapter I will first give an overview of the
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physiological platelet activation, and then discuss the role of factors such as insulin resistance,
hyperglycemia, dyslipidemia on platelet function. Next, I will describe the intracellular
mechanisms underlying platelet hyperreactivity in diabetes. Finally, the impact of diabetes on
the responsiveness to anti-platelet therapy will be discussed.
2. Physiological platelet activation
Platelets are anucleated cells generated from megakaryocytes, and after their release into the
blood, circulate for approximately 10 days. The main role of platelets is to maintain hemostasis.
Under normal conditions, platelet adhesion to the vascular wall is inhibited due to the anti-
thrombotic nature of the endothelial cell surface and the permanent release of anti-platelet
factors by the endothelium [3]. Following vascular injury, especially under the influence of
high shear stress, platelets tether and adhere to the exposed subendothelial collagen via the
von Willebrand factor (vWF)-mediated binding to platelet glycoprotein Ib/V/IX complex. The
initial interaction is subsequently strengthened by the interaction of collagen to its receptor
glycoprotein VI (GPVI) and the integrin α2β1. The ligation of these receptors activates Src
family tyrosine kinases (SFKs) which lead to the phosphorylation and activation of the
phospholipase Cγ2 (PLC γ2). The latter hydrolyses membrane Phosphatidylinositol-4, 5-
bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 1, 4, 5-triphosphate (IP3) which
respectively activates the protein kinase C (PKC) and stimulates the release of Ca2+ from the
intracellular stores. PKC binds to and phosphorylates the cytoplasmic tail of the β3 subunit of
the αIIbβ3 integrin complex, which then recruits talin and kindlin-3. This in turns causes a
conformational change in the extracellular domain of the integrin and enables the binding of
circulating fibrinogen (inside-out signalling). Fibrinogen links activated αIIbβ3 integrins of
neighbouring platelets and initiates platelet aggregation. After its binding, fibrinogen initiates
the so-called "outside-in" signalling of the integrin. This step includes the activation of SFKs
which promotes the tyrosine phosphorylation of β3 integrin and the binding of cytoskeletal
proteins leading to the activation of the phosphatidylinositide 3-kinases (PI3K) and platelet
adhesion. Ca2+ and DAG also act together to activate the calcium- and diacylglycerol-regulated
guanosine exchange factor (CalDAGGEF), a guanosine exchange factor important for the
activation of the small GTPase Rap1. The latter activates mitogen-activated protein kinases
(MAPKs) which are known to be upstream of the phospholipase A2 (PLA2)/cyclooxygenase
(COX) signalling cascade resulting into the production of thromboxane A2. PKC and MAPK
act in concert to stimulate the release of different second mediators from platelet granules.
These agonists; including adenosine diphosphate (ADP), serotonin and the formed throm‐
boxane A2 bind to their respective G protein–coupled receptors (GPCRs). Through the
activation of G protein-mediated signalling pathways, they can further increase their own
formation and/or release, thus acting as positive-feedback amplifying platelet responses by
recruiting additional platelets and promoting aggregation. (for review see references [4, 5])
(figure 1). In addition to stimulating degranulation, the increase in platelet [Ca2+)i also leads to
the activation of calpains, a family of Ca2+-dependent neutral cysteine proteases. While some
calpains are expressed only in specific tissues, platelets are known to express at least two
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isoforms of this enzyme i.e μ-calpain (calpain 1) and m-calpain (calpain 2). The μ- and m-
calpain were initially named for the Ca2+ concentration (micromolar versus millimolar)
required for their activation in vitro [6]. However it is now clear that additional mechanisms
such as phosphorylation also regulate their proteolytic activity [7]. Several reports have
highlighted the importance of μ- and m-calpain in platelet activation. Indeed, once activated,
calpains induce the limited proteolysis of a number of proteins implicated in cytoskeletal
rearrangement, degranulation and aggregation. Proteins identified to-date that are targeted
by calpain include spectrin, adducin and talin as well as platelet-endothelial cell adhesion
molecule-1 (PECAM-1), the myosin light chain kinase and N-ethylmaleimide-sensitive-factor
attachment receptor proteins such as N-ethylmaleimide sensitive factor attachment protein-23
and vesicle-associated membrane protein-3. Furthermore, μ-calpain modulates αIIbβ3
integrin-mediated outside-in signaling and platelet spreading by cleaving the β3 subunit of
the αIIbβ3 integrin [8]. In the final stages of platelet activation, phosphatidylserine, which is
normally sequestered in the inner leaflet of the plasma membrane, is relocated to the outer
leaflet leading to the shedding of microparticles and giving platelets a procoagulant surface.
After stimulation, Ca2+ is removed from the cytosol and sequestred into the intracellular stores
and/or extruded into the extracellular space by the action of the sarco-endoplasmic reticulum
Ca2+-ATPase (SERCA) and the plasma membrane Ca2+-ATPase (PMCA), respectively. Forma‐
tion of platelet plug or primary hemostasis is associated with the activation of the coagulation
cascade which results into fibrin deposition and linking (secondary hemostasis) and the
formation of a red clot. After the clot has been formed, platelets rearrange and contract their
intracellular actin/myosin cytoskeleton. Given that the intracellular actin network is connected
to the internal part of the integrin αIIbβ3, platelet contractile force on the fibrin network will
lead to “clot retraction”. Finally, the fibrin is slowly dissolved by the fibrinolytic enzyme,
plasmin, and the platelets are cleared by phagocytosis and wound healing will take place.
Platelets store quite high concentrations of chemokines, cytokines, growth factors and
vasoactive substances. The latter are sequestered into 2 major types of granules; α-granules
and dense granules. On the one hand, alpha-granules are known to contain growth factors
including vascular endothelial growth factor, platelet-derived growth factor, endostatin,
transforming growth factor-β; chemokines such as platelet factor 4 (CXCL4) and CCL5 and
adhesion molecules such as P-selectin. Dense granules, on the other hand, store mainly small
molecules (e.g ADP and serotonin) and ions (such as Ca2+ and Mg2+). Upon activation, platelets
release soluble proteins contained in their granules and redistribute some α-granules contents
to the membrane (e.g P-selectin, CD40 ligand). Given the variety of proteins released upon
platelet activation, it is clear that platelets may affect the vascular wall in different ways.
Indeed, beyond their role in hemostasis, platelets are involved in angiogenesis as well as in
vascular inflammation.
3. Effect of insulin resistance on platelet function
Insulin exerts an inhibitory effect on platelets but the intracellular mechanisms remain not
fully characterized and whether the effects are mediated by the insulin receptor is unclear.
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Indeed, there is no evidence of the expression of insulin receptor on platelets [9] and it is
speculated that the effects are rather mediated by the activation of insulin-like growth factor
(IGF) receptor [10, 11]. Insulin decreases thrombin-induced increase in Ca2+ and attenuates
agonist-induced platelet aggregation [12]. One of the mechanisms described to mediate the
anti-platelet effect of insulin is the activation of the AMP-activated protein kinase (AMPK) and
Akt by the PI3K [13]. Insulin can also inhibit Ca2+ mobilization by activating the inhibitory G-
protein Gi [14]. However, given that insulin can also stimulate the release of ADP [15], it is
assumed that whether insulin activates or inhibits platelets may depend on its concentration.
Although the insulin effect in platelets has been initially believed to involve the activation of
nitric oxide synthase (NOS), there are contradictory reports on the expression and function of
NOS in human platelets [13, 16]. Insulin resistance refers to the loss of response to insulin
stimulation. The molecular mechanisms of insulin resistance are complex but it has been
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Figure 1. Platelet major signalling pathways. Collagen binding either to GPVI or α2β1 integrin or vWF binding to
Gp1b-IX-V leads to the activation of Src family kinases and tyrosine phosphorylation of the phospholipase Cγ2. PLCγ2
cleaves phosphatidylinositol (4, 5)-bisphosphate PIP2 to generate inositol (1, 4, 5)-trisphosphate (IP3) and diacylglycer‐
ol (DAG). IP3 and DAG are responsible for the mobilization of calcium from intracellular stores leading to calpain acti‐
vation and the activation of isoforms of protein kinase C (PKC), respectively. Ca2+ and DAG activate the Ca2+ and
DAG-regulated guanosine exchange factor (CalDAGGEF) which in turn activate the small GTPase Rap1. The latter ac‐
tivates the mitogen-activated kinase (MAPK) which leads to thromboxane A2 generation, granule secretion and integ‐
rin activation. The released factors potentiate platelet signaling via the activation of G protein-coupled receptors/
phospholipase Cβ pathway. The binding of fibrinogen to activated integrin initiates platelet spreading by activating
the Phosphoinositide 3-kinase (PI3K) pathway.
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shown that the faculty of insulin to inhibit platelet activation is lost in diabetic patients [17]
and the inhibitory effect of insulin on the interaction of platelet with collagen and other agonists
is blunted by insulin resistance in obese subjects [18]. Moreover, in non diabetic, obese women,
there is a direct correlation between platelet reactivity assessed by thromboxane A2 generation
and insulin resistance [19].
4. Effect of hyperglycemia and AGEs
Despite the fact that diabetes is characterized by chronic hyperglycemia, there is evidence that
acute hyperglycemia can directly affect platelet reactivity. Indeed, a prospective randomised
double blind controlled study has shown that 24h euglycaemic treatment significantly
increased the plasma levels of the platelet and endothelial activation markers soluble P-selectin
and vWF [20]. Moreover, it has been shown that challenging healthy non-diabetic subjects with
24h hyperglycemia-hyperinsulinemia altered the insulin signaling pathway [21]. Indeed, the
glycogen synthase kinase 3β (GSKβ3) and the tyrosine phosphatase SHP2 as well as tissue
factor were upregulated on mRNA and protein levels while mRNA for the syntaxin 4-binding
protein was downregulated. High glucose can also increase calcium influx in platelets by
enhancing a PI3K-dependent transient receptor potential channel canonical type 6 [22]. The
latter is known to be significantly highly expressed in diabetic platelets. Hyperglycemia is able
to increase the expression and/or activity of PKC [23, 24], a central kinase in the regulation of
platelet activity. Another consequence of hyperglycemia in platelets is the induction of
mitochondrial dysfunction. One of the recent mechanisms linking hyperglycemia and
mitochondrial dysfunction is the activation of aldose reductase and subsequent ROS produc‐
tion which result to p53 phosphorylation [25] or the stimulation of the PLCγ2/PKC/p38α
MAPK pathway and the increase in TXA2 production [26]. More recent findings showed that
the hyperglycemia-induced platelet activation could be attributed to the downregulation of
different micro-RNA (miR) such as miR-223 and miR-146a. Indeed, low platelet and plasma
miR-223 and miR-146a expression has been associated with an increased risk for ischemic
stroke in patients with diabetes mellitus [27]. Many of the deleterious effects of glucose have
been attributed to its metabolite methylgyloxal (MG), a highly reactive dicarbonyl metabolite
that is generated endogenously by the nonenzymatic degradation of the glycolytic intermedi‐
ates, dihydroxyacetone phosphate and glyceraldehyde-3-phosphate [28]. It is known that
plasma levels of MG in diabetic individuals are enhanced. Study investigating the effect of MG
on platelets showed that acute application of MG to platelets increases intracellular Ca2+ levels
and activates classical PKCs at the same time as inhibiting PI3K/Akt and the β3-integrin
outside-in signalling. Moreover, in vivo, MG increases thrombus size but reduces its stability
in mice [29]. Although most of the effects of MG have been attributed to the formation of
advanced glycation end-products (AGEs) and the subsequent activation of the AGE receptor;
RAGE, this study has highlighted a direct effect of MG on platelets which may contribute to
the diabetes-associated platelet hyperaggregability. Several studies have shown that AGEs can
activate platelets and that platelets express RAGE. The expression of surface markers such as
P-selectin (CD62) and CD63 (a lysosomal glycoprotein) has been shown to be significantly
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increased by AGE stimulation [30] suggesting AGE-induced platelet degranulation. However,
this study failed to report the detailed intracellular mechanism involved. Studies performed
in mice could show that AGEs induce a prothrombotic phenotype via interaction with platelet
glycoprotein IV (CD36) [31]. The serum- and glucocorticoid-inducible kinase 1 (SGK1) has
been also suggested to mediate AGE-induced platelet hyperactivation [32]. Indeed, SGK1
expression is known to be regulated by hyperglycaemia and AGEs. In platelets, SGK1 increases
store-operated calcium entry (SOCE) and thereby regulates several Ca2+-dependent platelet
functions such as degranulation, integrin αIIbβ3 activation, phosphatidylserine exposure,
aggregation and thrombus formation.
5. Effect of dyslipidemia
The fact that glycemic control alone has proven insufficient to reduce thrombotic complica‐
tions in diabetic patients suggests that other factors may contribute to platelet hyperreactiv‐
ity  in  diabetes  [33].  One  feature  of  diabetes  is  the  presence  of  dyslipidemia  which  is
characterized by high plasma triglyceride concentration, reduced high density lipoprotein
(HDL)  concentration,  and  increased  concentration  of  low density  lipoprotein  (LDL)[34].
There is evidence that dyslipidemia contributes to the diabetes-associated platelet hyperac‐
tivation. By binding to a pertussis sensitive G-protein coupled receptor on platelets, LDL
induces an increase in cytosolic [Ca2+]i, IP3 formation and activation of PKC [35]. Howev‐
er,  the  pro-thrombotic  properties  of  LDL seem  to  be  rather  associated  to  its  oxidation.
Indeed, oxidized-LDL can directly interact with platelets specific receptors such as the lectin-
like oxidized LDL receptor-1 [36] or the CD36 [37, 38]. The latter involves the activation of
the MAPK c-Jun N-terminal kinase (JNK)2 and its upstream activator MKK4. Not only are
platelets activated by ox-LDL but activated platelets are also known to be able to form ox-
LDL via platelet gp91phox (NOX2)-dependent ROS generation [39] suggesting the contribu‐
tion of platelets to circulating ox-LDL. The formed ox-LDL has been demonstrated to be
either uptaken by monocytes [39] or amplify platelet activation [40]. On the molecular levels,
LDL activates the platelet arachidonic acid signalling cascade, i.e phosphorylation of p38
MAPK  and  cytosolic  phospholipase  A2,  leading  to  increased  TXA2  formation  [41].
Interestingly,  there  is  less  information  on  the  direct  effects  of  triglycerides  on  platelets.
However,  the link between hyperlipidemia and platelet  hyperactivation is  supported by
the fact that lipid-lowering agents possess anti-thrombotic properties [42, 43].
6. Dysregulation of calcium signalling
One of the characteristics of platelets from patients with type 2 diabetes is the alteration of
the intracellular Ca2+ homeostasis. Different mechanisms have been reported to be respon‐
sible for this abnormality. One of the mechanisms leading to the latter phenomenon is the
reduction in platelet Ca2+-ATPase activity in diabetic subjects [44, 45]. Moreover, the function
of the Na+/Ca2+  exchanger is  known to be significantly altered in platelets  from diabetic
The Non-Thrombotic Role of Platelets in Health and Disease182
patients [46]. Another mechanism contributing to the enhanced resting cytosolic calcium in
platelets from diabetic patients is the increased passive Ca2+ leakage rate from the intracel‐
lular stores [47]. Given that most of the intracellular signalling in platelets is regulated by
calcium, it is more than expected that a dysregulation in calcium homeostasis would affect
platelet function in many ways. One of the consequences of the increased [Ca2+]i in platelet
is the activation of calpains. Although calpain-mediated proteolysis is involved in physio‐
logical platelet activation, type 2 diabetes has been shown to be associated with the over-
activation of calpain in platelets [45] leading to marked changes in the platelet proteome
[48]. In platelets from diabetic patients, the integrin-linked kinase and septin-5 were found
to  be  new  calpain  substrates  and  their  cleavage  was  shown  to  be  involved  in  the  en‐
hanced platelet adhesion and spreading as well as enhanced α-granule secretion, respective‐
ly.  Moreover,  calpain was able to cleave the chemokine RANTES into a variant with an
enhanced chemotactic activity. The in vivo relevance of calpain in inducing the hyperreac‐
tivity of  platelets  from diabetic  patients was supported by the finding that  treatment of
diabetic  mice  with  calpain  inhibitor  preserved  the  platelet  proteome,  and  reversed  the
diabetes-associated platelet hyperactivation [48].
7. Increased apoptosis
Although being anucleated, there is evidence demonstrating that platelets possess the
necessary machinery to undergo apoptosis [49]. Among other mechanisms, calpain seems to
play an important role in platelet apoptosis [50, 51]. Indeed, although caspase is activated
during platelet apoptosis, this seems to be downstream of calpain activation. The increased
calpain activation in platelets from diabetic patients described above suggests that diabetic
platelets may be more prone to apoptosis. Several factors have been reported to induce platelet
apoptosis including the diabetes-associated oxidative stress which is an important stimulus
for inducing mitochondrial damage [52]. Mitochondria not only are the target of oxidative
stress but are also able to generate ROS therefore amplifying the reaction to oxidative stress
[52, 53]. Platelets from patients with type 2 diabetes demonstrate an increased ATP content
but decreased mitochondrial membrane potential [54] supporting the alteration of mitochon‐
drial function. Another mechanism involved in platelet apoptosis is the development of
endoplasmic reticulum (ER) stress. It has been shown that diabetes mellitus was associated
with the production of hyperreactive platelets expressing an altered protein disulfide isomer‐
ase and 78-kDa glucose-regulated protein [55]. Moreover, homocysteine, which levels are
known to be significantly increased in diabetic patients, has been shown to stimulate ER stress-
mediated platelet apoptosis by activating the caspase pathway [56]. One of the consequences
of platelet activation and apoptosis is the generation of intact membrane vesicles known as
microparticles. The formation of platelet-derived microparticles (PMPs) is known to be Ca2+-
and calpain-dependent. Although PMPs are involved in hemostasis due to their procoagulant
properties, elevated levels of PMPs in blood from diabetic patients has been suggested to
participate in the increased vascular complications in diabetes [57, 58].
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8. Increased mean platelet volume
Platelet reactivity and size have been shown to directly correlate. Indeed, young and large
platelets exhibit higher activity than old and small ones. The mean platelet volume (MPV) is
an indicator of the average size of platelets which has been largely used to investigate the
relationship between platelet size and activity. There is evidence that MPV is significantly
increased in diabetic patients and that it directly correlates with glycemic control [59-61].
9. Hyporesponsiveness to anti-platelet therapy
One feature of platelets from diabetic patients is their hyporesponsiveness to anti-platelet
therapy. Indeed, there is evidence that anti-platelet therapy is less effective in diabetic patients
when compared with patients without diabetes [62]. One example is the so-called “aspirin
resistance” in which diabetic patients are refractory to the anti-platelet effect of aspirin [63].
Aspirin or salicylic acid acetylates and irreversibly inhibits cyclooxygenase thereby inhibiting
the TXA2 formation. Aspirin has been also shown to activate the NO/cGMP pathway.
Although aspirin resistance is seen in the majority of diabetic patients, the exact molecular
mechanism is still unclear. One of the mechanisms proposed to mediate aspirin-resistance is
the increased glycation of platelet proteins which may alter the acetylation process [64]. Some
in vitro studies have also shown a direct link between hyperglycemia and aspirin resistance.
Certainly, high glucose can acutely reduce the antiaggregating effect of aspirin by inhibiting
the aspirin-induced activation of the NO/cGMP/PKG pathway without affecting the aspirin-
induced inhibition of TXA2 synthesis [65]. Given that acute stimulation of platelets with other
monosaccharides such as fructose and galactose was shown to lead to a similar alteration of
the aspirin effect on platelets and that lactic acid also impaired the inhibition of platelet
aggregation with aspirin, it has been suggested that lactic acid might be the mediator of the
glucose-induced inhibition of the aspirin effect in platelets [66]. Interestingly, the platelet
resistance seems to be specific to aspirin since hyperglycemia-induced platelet hyperactivation
in type 2 diabetes could be reversed by a nitric oxide-donating agent [67]. More recently, non-
HDL cholesterol has been reported to be an independent risk factor for aspirin resistance in
patients with type 2 diabetes [68].
Diabetes is also known to be associated to a reduced responsiveness of platelets to the P2Y12
ADP receptor antagonist clopidogrel [69, 70]. Although not directly investigated in diabetic
patients, upregulation of ADP receptor levels, increase in ADP exposure or accelerated platelet
turnover may contribute to clopidogrel resistance.
10. Conclusions
The fact that the diabetic milieu can affect platelet function in several ways explains the failure
of glycemic control alone to reduce the risk of atherothrombotic events in diabetic patients.
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Indeed, the increased platelet hyperreactivity is the result of complicated inter-regulated
mechanisms. Moreover, given that diabetic platelets are resistant to most anti-platelet therapy,
there is a need of new therapeutical strategies to improve platelet function in diabetes.
Certainly, management of both glycemia and dyslipidemia would improve the effects of anti-
platelet therapy. Moreover, the facts that calpain plays a key role in platelet activation and that
calpain activity is elevated in diabetic platelets, makes it tempting to suggest the Ca2+-activated
proteases as a promising therapeutic target to prevent thrombotic complications in diabetic
patients.
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